[Hand-foot syndrome after administration of tyrosinkinase inhibitors]

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Dermal toxicity is an increasing concern in cancer patients undergoing targeted therapies, particularly monoclonal antibodies and tyrosine kinase inhibitors (TKIs).
• Palmoplantar erythrodysesthesia syndrome, also known as hand-foot skin reaction (HFSR), is a frequent adverse effect associated with specific TKIs like sorafenib and sunitinib.
• Severe HFSR can negatively impact treatment adherence and patient quality of life.

Purpose of the Study:

• To highlight the occurrence and clinical significance of hand-foot skin reaction (HFSR) in patients receiving targeted anti-cancer therapies.
• To emphasize the importance of a multidisciplinary approach involving oncologists and dermatologists in managing HFSR.
• To underscore the role of patient education in preventing severe manifestations of HFSR.

Main Methods:

• Review of current literature on the dermal toxicity of targeted anti-cancer agents.
• Focus on the clinical presentation and management of palmoplantar erythrodysesthesia syndrome (HFSR).
• Analysis of the impact of HFSR on anti-cancer treatment protocols.

Main Results:

• Tyrosine kinase inhibitors (TKIs) such as sorafenib and sunitinib are frequently associated with the development of HFSR.
• HFSR can be a significant dose-limiting toxicity, potentially leading to treatment modifications or cessation.
• Proactive management strategies and patient guidance are crucial for mitigating HFSR severity.

Conclusions:

• Effective management of HFSR is essential for maintaining the dose intensity of targeted anti-cancer therapies.
• A collaborative approach between oncologists and dermatologists, coupled with patient education, can significantly improve outcomes and quality of life for cancer patients experiencing HFSR.
• Preventing severe HFSR ensures the continuity of cancer treatment and enhances patient well-being.